Research programme: thrombosis therapy - APT Therapeutics

Drug Profile

Research programme: thrombosis therapy - APT Therapeutics

Alternative Names: APT 102; APT 301; APT 302; APT 502

Latest Information Update: 05 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator APT Therapeutics
  • Developer APT Therapeutics; Washington University School of Medicine
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Platelet activating factor inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Myocardial infarction; Stroke

Highest Development Phases

  • Preclinical Stroke; Thrombosis
  • No development reported Cancer metastases

Most Recent Events

  • 03 Jan 2017 APT Therapeutics and AstraZeneca enter research and option collaboration for development of APT 102
  • 21 Nov 2014 No development reported - Preclinical for Cancer metastases in USA (IV)
  • 14 Oct 2014 Research programme: thrombosis therapy - APT Therapeutics is available for licensing as of 02 Oct 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top